New drug combo shows promise for tough cervical cancer cases
NCT ID NCT06416696
First seen Jan 11, 2026 · Last updated May 08, 2026 · Updated 20 times
Summary
This study tests whether adding the drug toripalimab to standard chemoradiotherapy helps people with high-risk, advanced cervical cancer live longer without the cancer growing. About 57 adults with stage III-IVA cervical cancer who haven't had prior treatment will receive toripalimab during and after chemoradiotherapy. The main goal is to see how many are cancer-free after two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
Conditions
Explore the condition pages connected to this study.